Brief: Acorda Therapeutics Inc Reports Quarterly Net Income Per Common Share Diluted Of $0.57

Acorda Therapeutics

09/03/2023 12:34

March 9 (Reuters) - Acorda Therapeutics Inc  ACOR.O :
    * ACORDA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR
2022
FINANCIAL RESULTS
    * ACORDA THERAPEUTICS INC - NASDAQ HEARINGS PANEL GRANTS
EXTENSION
UNTIL JUNE 20, 2023
    * ACORDA THERAPEUTICS - FOR QUARTER ENDED DEC 31, 2022,
REPORTED
INBRIJA U.S. NET REVENUE OF $9 MILLION, A 13.1% DECREASE
COMPARED TO SAME QUARTER IN 2021
    * ACORDA THERAPEUTICS INC - FOR FULL YEAR 2023, TARGETING
INBRIJA
U.S. NET REVENUE TO BE $38 - $42 MILLION
    * ACORDA THERAPEUTICS INC - TARGETING 2023 AMPYRA NET
REVENUE TO
BE $65 - $70 MILLION.
    * ACORDA THERAPEUTICS INC - TARGETING 2023 ADJUSTED OPEX TO
BE $93
- $103 MILLION AND ENDING CASH BALANCE TO BE $43 - $47 MILLION
    * ACORDA THERAPEUTICS INC - LONG-TERM GUIDANCE FOR NET
REVENUE,
2024-2027, REMAINS UNCHANGED FROM PREVIOUS GUIDANCE
    * ACORDA THERAPEUTICS INC QTRLY NET INCOME PER COMMON SHARE
-
DILUTED $0.57

Source text for Eikon:  ID:nBw5K449da 
Further company coverage:  ACOR.O 

 ((Reuters.Briefs@thomsonreuters.com;;))